Elmind Capital LP Acquires Shares of 112,000 Amylyx Pharmaceuticals, Inc. $AMLX

Elmind Capital LP acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 4th quarter, HoldingsChannel reports. The firm acquired 112,000 shares of the company’s stock, valued at approximately $1,353,000.

Several other institutional investors have also added to or reduced their stakes in AMLX. Meeder Asset Management Inc. acquired a new position in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $25,000. California State Teachers Retirement System acquired a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $28,000. Legal & General Group Plc acquired a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $47,000. BNP Paribas Financial Markets increased its holdings in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Amylyx Pharmaceuticals during the third quarter worth $48,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AMLX shares. Guggenheim raised their price objective on Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price objective on the stock. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Bank of America boosted their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Amylyx Pharmaceuticals Stock Up 1.3%

Shares of AMLX stock opened at $15.25 on Thursday. The firm has a market capitalization of $1.70 billion, a P/E ratio of -10.17 and a beta of -0.16. Amylyx Pharmaceuticals, Inc. has a twelve month low of $4.80 and a twelve month high of $18.60. The stock’s fifty day simple moving average is $15.15 and its 200 day simple moving average is $14.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.